Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro

Brain Research

Volumn 777, Issue 1-2, 1997, Pages 202-209

  Nakao, Naoyuki ^a   Nakai, Kunio ^a   Itakura, Toru ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antioxidant; CNQX; MK 801; Oxidative stress; Parkinson's disease; Rotenone

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; DIZOCILPINE; DOPAMINE; GLUTAMATE RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; MESENCEPHALON; METABOLIC INHIBITION; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE AGENTS; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MESENCEPHALON; NAD(P)H DEHYDROGENASE (QUINONE); NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; UNCOUPLING AGENTS;

EID: 0031589730     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01116-5     Document Type: Article

References (54)

1. [1] Y. Agid, F. Javoy-Agid, M. Ruberg, Biochemistry of neurotransmitter in Parkinson's disease, in: C.D. Marsden, S. Fahn (Eds.), Movement Disorder, Vol. 2, Butterworths, London, 1987, pp. 166-230.
2. [2] A.N. Basma, E.J. Morris, W.J. Nicklas, H.M. Geller, L-DOPA cytotoxicity to PC12 cells in culture is via its autoxidation, J. Neurochem. 64 (1995) 825-832.
3. [3] J. Blin, A.M. Bonnet, Y. Agid, Does levodopa aggravate Parkinson's disease?, Neurology 38 (1988) 1410-1416.
4. [4] S.B. Blunt, P. Jenner, C.D. Marsden, Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine, Mov. Disord. 8 (1993) 129-133.
5. [5] R.J. Bridge, J.Y. Koh, C.G. Hatalski, C.W. Cotman, Increased excitotoxic vulnerability of cortical cultures with reduced levels of glutathione, Eur. J. Pharmacol. 192 (1991) 199-200.
6. [6] A. Boveris, B. Chance, The mitochondrial generation of hydrogen peroxide, Biochem. J. 134 (1973) 707-716.
7. [7] R.H. Cha, P.C. O'Brien, Levodopa therapy and survival in idiopathic Parkinson's disease, Neurology 43 (1993) 1918-1926.
8. [8] Y.J. Chen, B.G. Jenkins, B.R. Rosen, Evidence of impairment of energy metabolism in Parkinson's disease using in vivo localized MR spectroscopy, Proc. Soc. Magn. Res. 1 (1994) 194.
9. [9] D.W. Choi, Glutamate neurotoxicity and diseases of the nervous system, Neuron 1 (1989) 623-634.
10. [10] G. Cohen, Catalase, glutathione peroxidase, superoxide dismutase and cytochrome P-450, in: A. Lajtha (Ed.), Handbook of Neurochemistry, Vol. 4, Plenum Press, New York, 1983, pp. 315-330.
11. [11] J.T. Coyle, P. Puttfarcken, Oxidative stress, glutamate, and neurodegenerative disorders, Science 262 (1993) 689-694.
12. [12] T.M. Dawson, V.L. Dawson, S.H. Snyder, A novel neuronal messenger molecule in brain: the free radical, nitric oxide, Ann. Neurol. 32 (1992) 297-311.
13. [13] D.T. Dexter, F.R. Wells, A.J. Lees, F. Agid, Y. Agid, P. Jenner, C.D. Marsden, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, J. Neurochem. 52 (1989) 1830-1836.
14. [14] L. Ernster, G. Dallner, G.F. Azzone, Differential effects of rotenone and amytal on mitochondrial electron and energy transfer, J. Biol. Chem. 238 (1963) 1124-1131.
15. [15] S. Fahn, G. Cohen, The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it, Ann. Neurol. 32 (1992) 804-812.
16. [16] M. Fekete, M. Traczy, K. Bihari, G. Katona, Dopamine/L-DOPA ratio in cerebrospinal fluid of parkinsonian patients treated with L-DOPA+benserazide, Psychopharmacology 82 (1984) 93-94.
17. [17] E.M. Frodl, N. Nakao, P. Brundin, Lazaroids improve the survival of cultured rat embryonic mesencephalic neurons, NeuroReport 5 (1994) 2393-2396.
18. [18] E. Hasegawa, K. Takeshige, T. Oishi, D.C. Murai, R.C. Duvoisin, 1-Methyl-4-phenylpyridinium (MPP+) induces NADH dependent superoxide formation, and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles, Biochem. Biophys. Res. Commun. 170 (1990) 1049-1055.
19. [19] F. Hefti, E. Melamed, J. Bhawan, R. Wurtman, Long term administration of L-DOPA does not damage dopaminergic neurons in the mouse, Neurology 31 (1981) 1194-1195.
20. [20] M. Lafon-Cazal, S. Pietri, M. Culcasi, J. Bockaert, NMDA-dependent superoxide production and neurotoxicity, Nature 364 (1993) 535-537.
21. [21] C.D. Marsden, J.D. Parkes, 'On-off' effects in patients Parkinson's disease on chronic levodopa therapy, Lancet 1 (1976) 292-296.
22. [22] C.D. Marsden, J.D. Parkes, Success and problems of long-term levodopa therapy in Parkinson's disease, Lancet 1 (1977) 345-349.
23. [23] C.D. Marsden, Parkinson's disease, J. Neurol. Neurosurg. Psychiatry 57 (1994) 672-681.
24. [24] I. Marey-Stemper, M. Gelman, M. Lévi-Strauss, A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation, J. Neurosci. 15 (1995) 5912-5918.
25. [25] M.A. Mena, B. Pardo, M.J. Casarejos, S. Fahn, J.G. de Yebenes, Neurotoxicity of levodopa on catecholamine-rich neurons, Mov. Disord. 7 (1992) 21-23.
26. [26] M.A. Mena, B. Pardo, C.L. Paino, S. Fahn, J.G. de Yebenes, Levodopa toxicity in foetal rat midbrain neurons in culture: modulation by ascorbic acid, NeuroReport 4 (1993) 438-440.
27. [27] Y. Mizuno, S. Ohta, M. Tanaka, S. Takiyama, K. Suzuki, T. Sato, H. Oya, T. Ozawa, Y. Kagawa, Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease, Biochem. Biophys. Res. Commun. 163 (1989) 1450-1455.
28. [28] C. Mytilineou, S.-K. Han, G. Cohen, Toxic and protective effects of L-DOPA on mesencephalic cell cultures, J. Neurochem. 61 (1993) 1470-1478.
29. [29] N. Nakao, E.M. Frodl, W.-M. Duan, H. Widner, P. Brundin, Lazaroids improve the survival of grafted rat embryonic dopamine neurons, Proc. Natl. Acad. Sci. USA 91 (1994) 12408-12412.
30. [30] N. Nakao, P. Odin, O. Lindvall, P. Brundin, Differential trophic effects of basic fibroblast growth factor, insulin-like growth factor-1, and neurotrophin-3 on striatal neurons in culture, Exp. Neurol. 138 (1996) 144-157.
31. [31] A. Novelli, J.A. Reilly, P.G. Lysko, R.C. Henneberry, Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced, Brain Res. 451 (1988) 205-212.
32. [32] N. Ogawa, M. Asanuma, Y. Kondo, Y. Kawada, M. Yamamoto, A. Mori, Differential effects chronic L-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine, Neurosci. Lett. 171 (1994) 55-58.
33. [33] C.W. Olanow, A radical hypothesis for neurodegeneration, Trends Neurosci. 16 (1994) 439-444.
34. [34] B. Pardo, M.A. Mena, S. Fahn, J.G. De Yébenes, Ascorbic acid protects against levodopa-induced neurotoxicity on catecholamine-rich human neuroblastoma cell line, Mov. Disord. 8 (1993) 268-273.
35. [35] B. Pardo, M.A. Mena, M.J. Casarejos, C.L. Paino, J.G. De Yébenes, Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants, Brain Res. 682 (1995) 133-143.
36. [36] T.L. Perry, D.V. Godin, S. Hansen, Parkinson's disease: a disorder due to nigral glutathione deficiency?, Neurosci. Lett. 33 (1982) 305-310.
37. [37] T.L. Perry, V.W. Young, M. Ito, J.G. Foulks, R.A. Wall, D.V. Godin, R.M. Clavier, Nigrostriatal dopaminergic neurons remain unchanged in rats given high doses of L-DOPA and carbidopa chronically, J. Neurochem. 43 (1984) 990-993.
38. [38] S. Przedborski, V. Jackson-Lewis, U. Muthane, H. Jiang, M. Ferreira, A.B. Naini, S. Fahan, Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity, Ann. Neurol. 35 (1993) 715-723.
39. [39] S. Przedborski, V. Jackson-Lewis, S. Fahan, Antiparkinsonian therapies and brain mitochondrial complex I activity, Mov. Disord. 10 (1995) 312-317.
40. [40] N.D. Quinn, D. Parkes, I. Janota, C.D. Marsden, Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period, Mov. Disord. 1 (1986) 65-68.
41. [41] P. Riederer, E. Sofic, W.-D. Rausch, B. Schmidt, G.P. Reynolds, K. Jelinger, M.B. Youdim, Transition metals, ferritin glutathione, and ascoribic acid in parkinsonian brains, J. Neurochem. 52 (1989) 515-520.
42. +) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon, J. Neurosci. Res. 43 (1996) 55-62.
43. [43] G. Scigliano, M. Musicco, P. Soliveri, I. Piccolo, P. Girotti, P. Giovanni, T. Caraceni, Mortality associated with early and late levodopa therapy initiation in Parkinson's disease, Neurology 40 (1990) 265-269.
44. [44] A.H.V. Schapira, J.M. Cooper, D.T. Dexter, J.B. Clark, P. Jenner, C.D. Marsden, Mitochondrial complex I deficiency in Parkinson's disease, J. Neurochem. 54 (1990) 823-827.
45. [45] K. Steece-Collier, T.J. Collier, C.D. Sladek, J.R. Sladek Jr., Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons, Exp. Neurol. 110 (1990) 201-208.
46. [46] Y. Tomozawa, S.H. Appel, Soluble striatal extracts enhance development of mesencephalic dopaminergic neurons in vitro, Brain Res. 399 (1986) 111-124.
47. [47] J.F. Turrens, A. Boveris, Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria, Biochem. J. 191 (1980) 421-427.
48. [48] G. Walkinshaw, C.M. Waters, Induction of apoptosis in cate-cholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease, J. Clin. Invest. 95 (1995) 2458-2464.
49. + toxicity in nigral dopaminergic neurons, NeuroReport 7 (1996) 921-923.
50. [50] D.M. Yurek, K. Steece-Collier, T.J. Collier, J.R. Sladek Jr., Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behaviour following neural grafting, Exp. Brain Res. 86 (1991) 97-107.
51. [51] D.D. Zeevalk, W.J. Nicklas, Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina, J. Pharmacol. Exp. Ther. 253 (1990) 1285-1292.
52. [52] D.D. Zeevalk, W.J. Nicklas, Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition, J. Pharmacol. Exp. Ther. 257 (1991) 870-878.
53. [53] G.D. Zeevalk, E. Derr-Yellin, W.J. Nicklas, NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid, J. Neurochem. 64 (1995) 455-458.
54. [54] G.D. Zeevalk, E. Derr-Yellin, W.J. Nicklas, Relative vulnerability of dopamine and GABA neurons in mesencephalic culture to inhibition of succinate dehydrogenase by malonate and 3-nitropropionic acid and protection by NMDA receptor blockade, J. Pharmacol. Exp. Ther. 275 (1995) 1124-1130.